Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)

B. D. Cheson, N. L. Bartlett, J. M. Vose, A. Lopez-Hernandez, A. L. Seiz, A. T. Keating, S. Shamsili, K. P. Papadopoulos, Kyriakos P. Papadopoulos

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalCancer
Volume118
Issue number17
DOIs
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cheson, B. D., Bartlett, N. L., Vose, J. M., Lopez-Hernandez, A., Seiz, A. L., Keating, A. T., Shamsili, S., Papadopoulos, K. P., & Papadopoulos, K. P. (2012). Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510). Cancer, 118(17). https://doi.org/10.1002/cncr.27384